SOUTH
SAN FRANCISCO, Calif., Oct. 4, 2024
/PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq:
RIGL) today announced that it has granted awards pursuant to
Rigel's Inducement Plan, approved by the Compensation Committee of
Rigel's Board of Directors and granted as an inducement material to
employees' entering into employment with Rigel, in accordance with
NASDAQ Listing Rule 5635(c)(4). Specifically, Rigel granted 35,944
stock options to fifteen non-executive employees vesting over four
years with a one-year cliff.
About Rigel
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL)
is a biotechnology company dedicated to discovering, developing and
providing novel therapies that significantly improve the lives of
patients with hematologic disorders and cancer. Founded in 1996,
Rigel is based in South San Francisco,
California. For more information on Rigel, the company's
marketed products and pipeline of potential products, visit
www.rigel.com.
Contact for Investors & Media
Rigel
Pharmaceuticals, Inc.
650.624.1232
ir@rigel.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/rigel-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-302267510.html
SOURCE Rigel Pharmaceuticals, Inc.